17 results about "Montelukast" patented technology

There is provided a compound of Formula I, wherein: Qa represents Z or A-Q-B, and Q is a structural fragment of Formula II,wherein: the squiggly lines, R and m have meanings given in the description, and wherein A and B have meanings given in the description, but may represent a peptide component of Formula (IV),[(W)r-Lys-X1-T-U-X2-Y] n- (W)r-Lys-X1-T-U-X2-Y (IV) (SEQ ID No: 1) in which n, r, T, W, X1, U, X2 and Y have meanings given in the description, each L independently represents a lipid as defined in the description, and D represents one or more optional montelukast moieties, which compounds are useful in medicine, including as pharmaceutical excipients, adhesives and film-forming materials and / or are useful in the treatment of conditions characterised by inflammation, including wounds, burns, and disorders of the mucosa, such as anorectal diseases, inflammatory bowel diseases, gynecological diseases and dental diseases.

The present invention relates to salts of Montelukast with β2 adrenergic agonists, pharmaceutical compositions containing the same and the use thereof in the treatment of respiratory inflammatory pathologies, obstructive pathologies and allergen-induced airway dysfunctions. The invention further relates to the process for preparing said salts.

Disclosed is a montelukast berberine double salt or composition with anti-inflammatory, antibacterial and immunomodulatory effects. Particularly, disclosed are a montelukast berberine quaternary ammonium salt with a structure as represented by formula (I), a double salt or a composition, a solvate, a hydrate, an isotope substitution or an isomer thereof.

Certain embodiments described herein include methods and formulations for treating or preventing symptoms and conditions associated with sepsis. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and / or modified-release elements, providing for drug delivery to the patient.

The present invention relates to montelukast for use in the treatment of erosive hand osteoarthritis. According to this use, montelukast can be administered either orally or topically, in the form of any suitable pharmaceutical composition. Patients suffering from erosive hand osteoarthritis treated with montelukast showed improvement in clinical symptoms and in radiological parameters, and also reported pain relief and hand functionality improvement.

The present invention relates to esters of Montelukast with corticosteroids, preferably with des-ciclesonide, triamcinolone, budesonide or flunisolide, pharmaceutical compositions containing the same and the use thereof in the treatment of several respiratory tract diseases, especially asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The invention further relates to the process for preparing said esters.

There is provided topical pharmaceutical formulations comprising montelukast, or a pharmaceutically acceptable salt of solvate thereof, as well as combination products comprising (a) at least one mussel adhesive protein or a derivative thereof; and (b) montelukast, or a pharmaceutically-acceptable salt or solvate thereof. The formulations and combination products find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and / or of condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.

A compound of formula I, L t - Q a - D b (I) wherein: Q a represents Z or A-Q-B, and Q is a structural fragment of formula II, (II) wherein: the wavy line, R and m have the meanings given in the description, and wherein A and B have the meanings given in the description, but can represent the peptide component of formula (IV), [(W) r - Lys-X 1 - T-U-X 2 - Y] n - (W) r - Lys-X 1 - T-U-X 2 - Y (IV) (SEQ ID No: 1) wherein n, r, T, W, X 1 , U, X 2 and Y have the meanings given in the description, each L independently represents a lipid as defined in the description, and D represents one or more optional montelukast moieties, is useful in medicine, including as a pharmaceutical excipient, adhesive and film forming material, and / or is useful in the treatment of conditions characterised by inflammation, including wounds, burns and mucosal disorders, such as anorectal disease, inflammatory bowel disease, gynaecological disease and dental disease.

The present invention relates to a composition containing montelukast and rupatadine, having improved stability, and, more specifically, to: a composition containing montelukast or a pharmaceutically acceptable salt, and rupatadine or a pharmaceutically acceptable salt thereof, the composition having a pH of 4 to 5.5 by an added pH regulator; and a preparation method therefor. The composition according to the present invention has a pH of 4 to 5.5 due to a pH regulator, thereby having reduced generation of related substances and having excellent stability.

The invention discloses application of montelukast in preparation of a medicine for preventing and treating hepatolenticular degeneration, and belongs to the technical field of biological medicines. According to the application disclosed by the invention, the montelukast is found to specifically block a cysteinyl leukotriene (CysLTs) receptor, cut off a CysLTs-mediated inflammation cascade reaction and remarkably inhibit the expression of chemotactic factors (such as CCL2) and subsequent pathological recruitment of macrophages, so that the liver is protected from secondary immune inflammation injury induced by copper toxicity. The discovery proves that montelukast can be used as a new anti-inflammatory and liver-protecting strategy without copper expelling dependence, can solve the problem of inflammatory injury which cannot be improved by the existing copper expelling medicine, and avoids possible side effects caused by powerful copper expelling. Besides, the montelukast is a marketed medicine (old medicine) which has been widely and clinically applied for many years, is clear in pharmacokinetics and high in safety, and has huge clinical transformation potential and application prospect as a medicine for preventing and treating hepatolenticular degeneration.

The present invention discloses a novel berberine quaternary ammonium salt, double salt or composition having anti-inflammatory, antibacterial and immunomodulatory effects, specifically a berberine quaternary ammonium salt, double salt or composition, solvate, hydrate, isotope-substituted product or isomer thereof having the structure represented by formula (I). #imgabs0#

The invention relates to the technical field of pharmaceutical engineering, in particular to preparation equipment and a preparation method of a montelukast intermediate. Comprising an evaporation tower and a base at the bottom of the evaporation tower, liquid inlet pipes are fixedly connected to the lower positions of the inner and outer walls of the evaporation tower; the upper port of the evaporation tower is sleeved with a tower cover; the lower end of the tower cover is lower than the upper end of the evaporation tower; an air outlet pipe is arranged at the top of the tower cover, and a discharge pipe is arranged at the bottom; the top of the tower cover is fixedly connected with a motor; a central shaft fixedly connected with the output end of the motor extends to the center of the inner side of the evaporation tower; the outer wall of the central shaft is fixedly connected with a spiral plate; the solution at the bottom of the evaporation tower can be continuously shifted into the spiral gap, so that the solution at the bottom of the evaporation tower is spread on the upper surface of the heated spiral plate, the heated area of the solution is increased, the evaporation effect of the solution is improved, and the evaporation crystallization efficiency of the potassium iodide or sodium iodide solution is improved.

The present application relates to treatment of Alzheimer's disease. More specifically, the present application relates to a method for treating, palliating or preventing progression of Alzheimer's disease in a subject in need thereof, or improving cognition, suicidality, behavioral disturbance, clinical global impression, and / or functional ability in a subject with Alzheimer's disease, or improving global cognition, the method comprising administering to the subject at least about 50 mg of Montelukast daily, wherein the Montelukast is formulated as an oral dosage film for oral administration.

The application belongs to the technical field of biological medicine, and relates to application of ENT-montelukast or a derivative thereof in preparation of a drug for treating a disease with TMEM164 as a target. The application is verified by surface plasmon resonance technology (SPR) screening, and it is proved that the derivative such as ENT-montelukast or a salt thereof can strongly bind to TMEM164 protein; after biological verification, it is indicated that a TMEM164 overexpression cell line treated by the derivative such as ENT-montelukast or a salt thereof is significantly and effectively improved in sensitivity to ferroptosis. It is indicated that the derivative such as ENT-montelukast or a salt thereof has selective inhibition on TMEM164, and then a technical scheme of application of ENT-montelukast or a derivative thereof in preparation of a drug for treating a disease with TMEM164 as a target is proposed. The scheme provided by the application provides a new way for disease treatment targeting TMEM164.

The present invention relates to methods of reducing occurrence or severity of infusion-related reactions (IRRs) in a subject treated with an anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody, comprising administering (a) dexamethasone; (b) montelukast; or (c) methotrexate to the subject.

The present invention relates to a novel pharmaceutical composition comprising rupatadine or a pharmaceutically acceptable salt thereof and montelukast or a pharmaceutically acceptable salt thereof. The novel pharmaceutical composition can be manufactured by a simple method and exhibits excellent compatibility of the two APIs while allowing the two APIs to have excellent bioavailability.